NTLA

Intellia Therapeutics (NTLA)

About Intellia Therapeutics (NTLA)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Details

Daily high
$18.00
Daily low
$17.46
Price at open
$17.68
52 Week High
$34.87
52 Week Low
$17.43
Market cap
1.8B
Dividend yield
0.00%
Volume
2.1M
Avg. volume
1.6M
P/E ratio
-3.26

Intellia Therapeutics News

Details

Daily high
$18.00
Daily low
$17.46
Price at open
$17.68
52 Week High
$34.87
52 Week Low
$17.43
Market cap
1.8B
Dividend yield
0.00%
Volume
2.1M
Avg. volume
1.6M
P/E ratio
-3.26